<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of peripheral T cell lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of peripheral T cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial treatment of peripheral T cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Jacobsen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas in adults. </p><p>This topic discusses management of the following subtypes of PTCL:</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS)</p><p class="bulletIndent1"><span class="glyph">●</span>Angioimmunoblastic T cell lymphoma (AITL)</p><p class="bulletIndent1"><span class="glyph">●</span>Enteropathy-associated T cell lymphoma (EATL)</p><p></p><p>Classification of lymphomas and clinical presentation and diagnosis of these PTCL subtypes are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Lymphoid neoplasms'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4727.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4704.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma"</a>.)</p><p></p><p>Management of PTCL, NOS; AITL; and EATL is divided into induction chemotherapy and post-induction management. Because these diseases are less responsive to chemotherapy than many other types of lymphoma, induction therapy is often guided by interim response assessment. After completion of induction therapy, post-induction management is guided by disease stage, prognosis, and medical fitness. </p><p>Management of relapsed and refractory PTCL is discussed separately. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p>This topic does <strong>not</strong> discuss management of the following categories of T cell lymphomas, which are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99237.html" rel="external">"Initial treatment of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4736.html" rel="external">"Treatment and prognosis of adult T cell leukemia-lymphoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16616.html" rel="external">"Treatment of Sézary syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16591.html" rel="external">"Treatment of extranodal NK/T cell lymphoma, nasal type"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>The initial evaluation of patients with non-Hodgkin lymphoma (NHL) must establish the histologic subtype, disease stage  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 1</a>), and the patient’s suitability for intensive treatments, including hematopoietic cell transplantation (HCT).</p><p>General approaches to the diagnostic work-up and staging of NHLs are presented separately. (See  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas"</a>.)</p><p>Diagnosis and classification of T cell NHLs are discussed separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Mature T cell or NK cell lineage'</a>.)</p><p class="headingAnchor" id="H1856386864"><span class="h2">Clinical and laboratory assessment</span><span class="headingEndMark"> — </span>Pretreatment evaluation determines the disease stage and identifies comorbidities that may influence treatment choices. PTCL most often involves nodal sites, but many patients present with extranodal involvement, such as liver, bone marrow, gastrointestinal (GI) tract, and skin.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – History should include the presence of constitutional symptoms (unexplained fevers, sweats, weight loss).</p><p></p><p class="bulletIndent1">Physical examination must evaluate node-bearing areas and the size of the liver and spleen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> – Studies include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> – Complete blood count with differential count.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum chemistries</strong> – Basic metabolic panel, including electrolytes; liver function tests, including lactate dehydrogenase (LDH); and renal function tests, including uric acid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infectious</strong> – Hepatitis B and human immunodeficiency virus (HIV) testing. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow examination</strong> – Unilateral bone marrow aspiration and biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Positron emission tomography (PET)/computed tomography (CT) is performed prior to treatment; it is performed again after three cycles of treatment (PET3) and following completion of initial therapy (end-of-induction PET). Most cases of PTCL are fluorodeoxyglucose (FDG)-avid.</p><p></p><p class="bulletIndent1">Contrast-enhanced CT of the chest, abdomen, and pelvis is helpful for staging and initial measurement of disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart</strong> – Echocardiogram or radionucleotide ventriculogram to estimate cardiac ejection fraction if an anthracycline may be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility</strong> – People of childbearing potential should receive counseling about potential effects of treatment on fertility and options for fertility-preserving measures. (See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p></p><p class="headingAnchor" id="H853699139"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Pathology findings are important for classifying PTCL subtypes and they affect treatment choices and prognosis.</p><p>PTCL should be diagnosed and classified according to either the International Consensus Classification [<a href="#rid1">1</a>] or the World Health Organization 5<sup>th</sup> edition [<a href="#rid2">2</a>], as discussed separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Mature T cell or NK cell lineage'</a>.)</p><p>An excisional or incisional biopsy specimen is preferred, but core needle biopsies may be acceptable in some circumstances. A fine needle aspirate is not adequate for initial diagnosis and classification. The biopsy specimen should be reviewed by a hematopathologist with expertise in PTCL.</p><p>Evaluation of the biopsy specimen should confirm the T cell immunophenotype by immunohistochemistry and/or flow cytometry, while molecular studies can analyze T cell receptor (<em>TCR</em>) rearrangement and other features. Pathologic evaluation should include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD30 expression</strong> – For the purpose of selecting front-line therapy, we consider CD30 expression by ≥1 percent of tumor cells to define a CD30-positive PTCL. (See <a class="local">'Overview of management'</a> below.)</p><p></p><p class="bulletIndent1">Immunohistochemical detection of CD30 expression is not standardized. It is important to ensure that CD30 expression is assessed for tumor cells and not inflammatory cells, such as immunoblasts that can also express CD30.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular analysis</strong> – Molecular findings are associated with prognosis, but they do not guide current management.</p><p></p><p class="bulletIndent1">As an example, most patients with PTCL, not otherwise specified (NOS) can be grouped according to either <em>GATA3</em> overexpression (one-third of patients) or <em>TBX21</em> overexpression (one-half of cases) [<a href="#rid3">3,4</a>]. PTCL, NOS with <em>GATA3</em> overexpression is associated with a very poor prognosis [<a href="#rid3">3,5,6</a>]. PTCL, NOS with <em>TBX21</em> overexpression is generally associated with a better prognosis, although a subset of <em>TBX21</em>-high tumors with a cytotoxic gene expression profile and/or <em>DNMT3A</em> mutations have very poor prognosis [<a href="#rid3">3,7</a>].</p><p></p><p class="headingAnchor" id="H118046203"><span class="h2">Fitness/transplant eligibility</span><span class="headingEndMark"> — </span>Medical fitness influences management choices for PTCL.</p><p>Performance status should be assessed  (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 2</a>). </p><p>We assess comorbid conditions (eg, heart, lung, kidney, liver disease) that might affect treatment, including eligibility for autologous HCT. Many institutions limit autologous HCT to patients ≤65 to 70 years without major medical comorbidities, but practices vary. Eligibility criteria for autologous HCT are discussed separately. (See  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H723101210"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Application of a prognostic scoring system is important for post-induction management decisions. (See <a class="local">'Postinduction management'</a> below.)</p><p>The International Prognosis Index (IPI)  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 3</a>) [<a href="#rid8">8</a>] or the Prognostic Index for PTCL (PIT) [<a href="#rid9">9</a>] can be used to estimate prognosis in patients with PTCL. Disease-specific prognostic indices, including one specific to angioimmunoblastic T cell lymphoma (AITL), have been developed, but the IPI and PIT are acceptable for routine clinical use [<a href="#rid10">10</a>].</p><p>The IPI was originally developed for aggressive B cell lymphomas [<a href="#rid8">8</a>], but it is widely used for T cell lymphomas. PIT was specifically developed for patients with PTCL [<a href="#rid9">9</a>]. Both IPI and PIT have prognostic value in PTCL and were associated with outcomes of patients with PTCL in multiple studies [<a href="#rid9">9,11-17</a>]. (See  <a class="medical medical_review" href="/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified", section on 'International Prognostic Index (IPI)'</a>.)</p><p>Inferior survival has been associated with male sex, age ≥60 years, stage III/IV, performance status ≥2, bulky tumor (ie, ≥10 cm), and elevated serum LDH [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1030455255"><span class="h1">OVERVIEW OF MANAGEMENT</span><span class="headingEndMark"> — </span>PTCL comprises a heterogeneous group of T cell lymphomas. This topic discusses management of the following subtypes: </p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angioimmunoblastic T cell lymphoma (AITL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enteropathy-associated T cell lymphoma (EATL)</p><p></p><p>We strongly encourage participation in a clinical trial, when available.</p><p>Management of PTCL involves:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of an induction regimen</strong> – Induction therapy is stratified according to CD30 expression by the tumor cells  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CD30 positive</strong> – We consider cases of PTCL in which CD30 is expressed by ≥1 percent of tumor cells to be CD30 positive. Front-line therapy of CD30-positive PTCL generally includes <a class="drug drug_general" data-topicid="16806" href="/d/drug information/16806.html" rel="external">brentuximab vedotin</a> (BV), a CD30-directed antibody-drug conjugate. (See <a class="local">'CD30 positive'</a> below.)</p><p></p><p class="bulletIndent2">CD30 expression is highly variable, and it is uncertain if response to BV is directly related to the percentage of tumor cells that express CD30. The package insert for BV does not specify a threshold for CD30 expression for use with chemotherapy in the front-line setting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CD30 negative</strong> – For cases with little or no CD30 expression, standard induction therapy generally uses anthracycline-based chemotherapy and is guided by age and medical fitness: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Medically fit, younger patients</strong> – More intensive chemotherapy regimens are generally limited to patients ≤60 or 65 years without major comorbidities. (See <a class="local">'Fit, younger patients'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Older or less-fit patients</strong> – For older patients or those with significant comorbid illnesses, lower intensity therapy is generally used to avoid excess toxicity. (See <a class="local">'Older or less-fit patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response-guided therapy</strong> – Because the response to induction therapy is often incomplete or transient, many experts use response-guided treatment, in which positron emission tomography (PET) is repeated after three cycles of induction chemotherapy (PET3)  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>). This approach enables quicker recognition of refractory disease and earlier implementation of care for refractory disease. (See <a class="local">'PET3 response'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-of-induction PET</strong> – After completing induction therapy, end-of-induction PET guides further management. (See <a class="local">'End-of-induction PET'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-induction management</strong> – Post-induction management is stratified according to disease stage, prognostic score, and fitness  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>), as discussed below. (See <a class="local">'Postinduction management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – After completing therapy, patients are monitored for relapse and treatment-related adverse effects, as discussed below. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p>Our approach to management of PTCL is consistent with guidelines from the United States National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology, the British Committee for Standards in Haematology, and the Italian Society of Hematology [<a href="#rid19">19-22</a>].</p><p class="headingAnchor" id="H4"><span class="h1">INDUCTION THERAPY</span><span class="headingEndMark"> — </span>The choice of induction regimen for PTCL is stratified according to tumor expression of CD30  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>), which can be targeted by <a class="drug drug_general" data-topicid="16806" href="/d/drug information/16806.html" rel="external">brentuximab vedotin</a> (BV), a CD30-directed monoclonal antibody linked to monomethyl auristatin E. We consider cases in which immunohistochemistry (IHC) demonstrates CD30 expression by ≥1 percent of tumor cells to be CD30 positive, but CD30 expression is not standardized and some patients with lower levels of CD30 expression respond to BV. Although the most definitive trial (ECHELON-2, described below) required CD30 expression by ≥10 percent of tumor cells for enrollment, there is no consensus threshold, the package insert does not specify a minimum level of expression, and there is no clear correlation between level of expression and response [<a href="#rid23">23,24</a>].</p><p>We use response-guided therapy, in which positron emission tomography (PET) is repeated after the first three cycles of induction therapy (PET3)  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>), because a significant proportion of patients do not respond robustly, or they relapse early during treatment. Response-guided therapy enables early recognition of refractory disease and avoids excessive toxicity from ineffective systemic therapy. Results from PET3 inform the decision whether to complete induction therapy with three additional chemotherapy cycles or proceed to management for refractory disease. (See <a class="local">'PET3 response'</a> below.)</p><p class="headingAnchor" id="H1593511256"><span class="h2">CD30 positive</span><span class="headingEndMark"> — </span>For patients with CD30-positive PTCL, we suggest BV+CHP (<a class="drug drug_general" data-topicid="16806" href="/d/drug information/16806.html" rel="external">brentuximab vedotin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>)  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>), rather than other chemotherapy regimens, based on acceptable toxicity and a trend toward superior outcomes for patients with CD30-positive PTCL [<a href="#rid23">23,25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BV+CHP administration</strong> – BV+CHP is similar to CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>)  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>), but vincristine is replaced by BV 1.8 mg/kg intravenously on day 1 of each cycle. The dose of BV should be adjusted for mild hepatic impairment.</p><p></p><p class="bulletIndent1">Three initial cycles of BV+CHP are followed by interim restaging with PET3. (See <a class="local">'PET3 response'</a> below.)</p><p></p><p class="bulletIndent1">Further management is guided by the PET3 response  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>) (see <a class="local">'PET3 response'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete response (CR) or partial response (PR)</strong> - For patients with complete response (CR) or partial response (PR) on PET3, we complete induction therapy by treating with three additional cycles of BV+CHP (six cycles total).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease (ie, less than PR)</strong> - Patients with a PET3 response less than PR are managed for refractory disease. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1">The US Food and Drug Administration (FDA) approved BV in combination with CHP for initial treatment of adults with CD30-expressing PTCL, including angioimmunoblastic T cell lymphoma (AITL) and PTCL, not otherwise specified (NOS). The European Medicines Agency approved BV+CHP only for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Prescribing information for BV carries a warning about the rare occurrence of progressive multifocal leukoencephalopathy. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – The preference for BV+CHP as initial therapy for CD30-positive PTCL is based on results from the ECHELON-2 trial that randomly assigned patients with CD30-positive T cell lymphomas to BV+CHP versus CHOP [<a href="#rid23">23,25</a>].</p><p></p><p class="bulletIndent1">ECHELON-2 reported superior outcomes with BV+CHP, but the benefits were not statistically significant for histologies other than sALCL; importantly, the trial was not powered to determine efficacy according to non-sALCL subtypes. Among 452 enrolled patients, only one-third had non-sALCL subtypes: PTCL, NOS (13 percent); AITL (13 percent); and enteropathy-associated T cell lymphoma (EATL; 1 percent). For the entire trial population, BV+CHP achieved superior overall survival (OS) and progression-free survival (PFS), but with median follow-up of four years, there was no significant difference in OS or PFS for the 72 patients who had non-sALCL subtypes [<a href="#rid23">23</a>]. For patients with AITL, estimated five-year OS was 68 versus 63 percent with CHOP, while for PTCL, NOS, five-year OS was 46 versus 36 percent. There was no apparent correlation between the level of CD30 expression and the likelihood of response among patients with non-sALCL histologies.</p><p></p><p class="bulletIndent1">Treatment-related toxicity was similar in both trial arms of ECHELON-2. There was more grade ≥3 diarrhea (6 versus 1 percent) with BV+CHP; other grade ≥3 adverse events included neutropenia (35 percent), peripheral sensory neuropathy (4 percent), and nausea (2 percent) [<a href="#rid25">25</a>]. Adverse events leading to death occurred in 3 and 4 percent of patients treated with BV+CHP and CHOP, respectively. With longer follow-up, peripheral neuropathy resolved in three-quarters of affected patients in both trial arms [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">Outcomes for patients with anaplastic large cell lymphoma (ALCL) in ECHELON-2 are presented separately. (See  <a class="medical medical_review" href="/d/html/99237.html" rel="external">"Initial treatment of systemic anaplastic large cell lymphoma (sALCL)", section on 'Induction therapy'</a>.)</p><p></p><p>An ongoing phase 2 study (NCT03113500) is evaluating the safety and efficacy of adding BV to CHOEP-based chemotherapy (BV plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>), followed by BV consolidation in patients with newly diagnosed CD30-positive PTCL.</p><p class="headingAnchor" id="H62912807"><span class="h2">CD30 negative</span><span class="headingEndMark"> — </span>For CD30-negative PTCL, we stratify treatment according to age and medical fitness  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>). Many experts consider an age threshold for more aggressive treatments to be 60 or 65 years, but we favor functional assessment of fitness, rather than a strict age limit. (See <a class="local">'Fitness/transplant eligibility'</a> above.)</p><p>The mainstay of induction therapy for CD30-negative PTCL is anthracycline-based chemotherapy. Compared with non-anthracycline-containing regimens, anthracycline-based therapy was associated with a trend toward superior survival (hazard ratio [HR] 0.71 [95% CI 0.48-1.05]) in a study of 499 patients with PTCL [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1192722123"><span class="h3">Fit, younger patients</span><span class="headingEndMark"> — </span>For medically fit, younger patients with CD30-negative PTCL, we suggest CHOEP rather than CHOP  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>) or more intensive regimens. Compared with CHOP, CHOEP is associated with better clinical outcomes and moderately increased toxicity; other intensive regimens are associated with similar outcomes but substantially greater toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CHOEP administration</strong> – Many experts limit use of CHOEP to medically fit patients ≤60 or 65 years because of toxicity.</p><p></p><p class="bulletIndent1">In CHOEP, intravenous <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> 100 mg/m<sup>2</sup> on days 1 through 3 of each 21-day cycle is added to the CHOP regimen  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>). An alternate version of CHOEP administers intravenous etoposide 100 mg/m<sup>2</sup> on day 1 of CHOP, followed by oral etoposide 200 mg/m<sup>2</sup> on days 2 and 3 of each 21-day cycle. The higher oral dose of etoposide is necessary due to poor bioavailability with oral administration.</p><p></p><p class="bulletIndent1">PET3 is performed after the first three cycles of CHOEP  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>) in order to decide whether to give three additional cycles of induction or treat for refractory PTCL (as described above for BV+CHP). (See <a class="local">'PET3 response'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – No randomized trials have directly compared CHOEP with CHOP, but most studies indicate that CHOEP is associated with better outcomes in patients ≤65 years. Further treatment intensification of CHOEP or addition of agents to a CHOP backbone were not associated with improved outcomes for patients with PTCL, but many caused greater toxicity [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">Studies that compared CHOEP and CHOP follow; outcomes with other regimens are presented below. (See <a class="local">'Other induction regimens'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Swedish lymphoma registry</strong> – Outcomes were more favorable with CHOEP than with CHOP in this registry study of 755 patients, which included 256 patients with PTCL, NOS; 104 with AITL; and 68 with EATL [<a href="#rid28">28</a>]. For patients ≤60 years, CHOEP was associated with superior PFS (HR 0.49 [95% CI 0.29-0.83]) and trends toward better OS (HR 0.58 [95% CI 0.33-1.01]) and higher overall response rate (ORR; 81 versus 70 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dutch registry</strong> – This national registry, which included 1427 patients (AITL 21 percent; PTCL, NOS 44 percent; ALCL 35 percent), reported that CHOEP was associated with superior survival [<a href="#rid29">29</a>]. Five-year OS was superior for patients treated with CHOEP compared with CHOP (64 versus 44 percent, respectively), and there was a trend toward higher CR rate (60 versus 49 percent). ORR was 44 percent for patients with AITL and 32 percent for PTCL, NOS. The risk of mortality was similar with both regimens when adjusted for age, PTCL subtype, prognostic score, and subsequent transplantation (except for patients with anaplastic lymphoma kinase [ALK]-positive ALCL, who had superior survival with CHOEP).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>German studies</strong> – CHOEP was associated with superior, three-year event-free survival (EFS) in patients ≤60 years (61 versus 48 percent), but there was no difference in OS among 320 patients with PTCL (including 70 with PTCL, NOS and 28 with AITL) in a series of prospective studies by the German High-Risk Lymphoma Study Group [<a href="#rid30">30</a>]. No benefit for CHOEP was seen in patients &gt;60 years, due to additional toxicity and treatment delays.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Czech registry</strong> – Among patients in the Czech lymphoma registry, CHOEP was associated with superior, five-year OS (66 versus 48 percent) and better, five-year PFS (59 versus 33 percent) compared with CHOP, on an intention-to-treat basis [<a href="#rid18">18</a>]. However, it is uncertain if long-term outcomes were related to the induction regimen alone, as more patients who received CHOEP were planned for autologous hematopoietic cell transplantation (HCT; 57 versus 41 percent of patients).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Korean registry</strong> – A retrospective review of 748 patients who received anthracycline-based therapy reported that addition of <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> to CHOP-like therapy did not improve outcomes, but it was associated with longer hospitalizations and more transfusions [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">Ongoing studies include a phase 3 trial of CHOP versus CHOP plus <a class="drug drug_general" data-topicid="8797" href="/d/drug information/8797.html" rel="external">azacitidine</a> plus chidamide (NCT05075460) and a study of CHOP plus <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> (NCT04423926).</p><p></p><p class="headingAnchor" id="H2816587462"><span class="h3">Older or less-fit patients</span><span class="headingEndMark"> — </span>For older or less medically fit individuals of any age with CD30-negative PTCL, we favor CHOP induction therapy  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>) to avoid the increased toxicity associated with CHOEP.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CHOP administration</strong> – CHOP  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>) is given every three weeks for three cycles, followed by PET3  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>) to guide completion of six total cycles of CHOP (for patients with CR or PR) versus management for refractory disease (as discussed above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Outcomes with CHOP in the ECHELON-2 trial are presented above. (See <a class="local">'Fit, younger patients'</a> above.)</p><p></p><p class="bulletIndent1">Outcomes are generally inferior for older patients with PTCL. As an example, among 320 patients with PTCL in a series of prospective German studies, patients ≤60 years had more favorable OS (HR 1.7 [95% CI 1.2-2.5]) and EFS (HR 1.5 [95% CI 1.1-2.2]) compared with older patients [<a href="#rid30">30</a>]. The most common grade ≥3 adverse event associated with CHOP is neutropenia (approximately 60 percent), while other adverse events include mild to moderate alopecia, nausea, vomiting, and infusion-related reactions; treatment-related mortality with CHOP is approximately 1 percent.</p><p></p><p class="headingAnchor" id="H1955989610"><span class="h2">Interim restaging</span><span class="headingEndMark"> — </span>We assess response to induction therapy by PET after three cycles of induction therapy (PET3 response). PET is again performed after completing six cycles of treatment (end-of-induction PET response).</p><p class="headingAnchor" id="H412051816"><span class="h3">Response criteria</span><span class="headingEndMark"> — </span>Response to therapy is judged using the five-point PET scale (Deauville score)  (<a class="graphic graphic_table graphicRef108973" href="/d/graphic/108973.html" rel="external">table 5</a>), according to Lugano criteria [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CR</strong> – PET score 0 to 3 (with or without a residual mass) and no evidence of bone marrow involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PR</strong> – PET score 4 or 5 with reduced uptake compared with baseline, no new progressive lesions, and bone marrow activity less than baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable disease</strong> – PET score 4 or 5 (unchanged from baseline), no new lesions, and bone marrow activity unchanged from baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive disease</strong> – PET score 4 or 5 (increased compared with baseline), new sites of disease, and new or recurrent bone marrow activity.</p><p></p><p class="headingAnchor" id="H3635122715"><span class="h3">PET3 response</span><span class="headingEndMark"> — </span>PET3 response guides further management  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CR or</strong> <strong>PR</strong> – Complete the planned course of induction chemotherapy (usually six cycles total). (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable or progressive disease</strong> – Proceed to treatment for relapsed/refractory (r/r) PTCL, as described separately. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H3954577450"><span class="h1">END-OF-INDUCTION PET</span><span class="headingEndMark"> — </span>Positron emission tomography (PET) is repeated within six to eight weeks of completing chemotherapy [<a href="#rid33">33</a>], with response judged as described above. (See <a class="local">'Response criteria'</a> above.)</p><p>Post-induction management is guided by stage and prognostic score, along with the findings from the end-of-induction PET, as described below  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>). (See <a class="local">'Postinduction management'</a> below.)</p><p class="headingAnchor" id="H3664633517"><span class="h1">POSTINDUCTION MANAGEMENT</span><span class="headingEndMark"> — </span>We consider the following features in selecting postinduction management for patients with PTCL  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic score</strong> – Either the International Prognosis Index (IPI)  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 3</a>) [<a href="#rid8">8</a>] or the Prognostic Index for PTCL (PIT) [<a href="#rid9">9</a>] can be used to estimate prognosis in patients with PTCL. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1">We consider adverse prognosis for PTCL to be either:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IPI score ≥2</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PIT score ≥1</p><p></p><p class="bulletIndent1">There are no consensus criteria for an adverse clinical prognostic score in PTCL. The association of outcomes with prognostic scores for PTCL is discussed separately. (See  <a class="medical medical_review" href="/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified", section on 'International Prognostic Index (IPI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage</strong> – Stage at diagnosis  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 1</a>), together with the prognostic score (described above), are used to stratify post-induction management:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage I and favorable prognosis</strong> (See <a class="local">'Stage I with favorable prognostic score'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stages II-IV or adverse prognostic score</strong> (See <a class="local">'Advanced stage or adverse prognosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age and fitness for transplantation</strong> – Management of patients with advanced stage PTCL or an adverse prognostic score, is informed by eligibility for hematopoietic cell transplantation (HCT). Many institutions limit HCT to patients ≤65 years who have no major medical comorbidities. Details of eligibility for autologous HCT are discussed separately. (See  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H2112926038"><span class="h2">Stage I with favorable prognostic score</span><span class="headingEndMark"> — </span>Management is guided by results from the end-of-induction PET  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete response (CR) or partial response (PR)</strong> - For CR or PR in patients with stage I PTCL and a favorable prognostic score, we suggest radiation therapy (RT), based on good outcomes and modest toxicity. Management should be individualized; some patients choose observation to avoid the inconvenience and possible adverse effects (AEs) of RT. AEs associated with HCT are not warranted, considering the favorable prognosis in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable disease or progressive disease</strong> - Patients with stable or progressive disease on end-of-induction positron emission tomography (PET) are treated for refractory PTCL, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p>Outcomes in this setting are generally favorable. As an example, one study reported 50 to 75 percent five-year OS [<a href="#rid11">11</a>]. Small retrospective studies of adjuvant RT for early-stage PTCL have reported mixed results:</p><p class="bulletIndent1"><span class="glyph">●</span>There was a trend toward superior outcomes when RT was used as consolidation therapy among 118 patients with stage I to II PTCL in data from the Swedish lymphoma registry [<a href="#rid28">28</a>]. Compared with patients who received chemotherapy only, for the 32 patients who received RT after chemotherapy, there was a trend toward improved five-year OS (73 versus 53 percent, respectively; HR 0.58 [95% CI 0.32-1.05]) and improved five-year PFS (60 versus 45 percent, respectively; HR 0.57 [95% CI 0.32-1.03]). However, when compensating for other risk factors, there was no risk reduction associated with RT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter study of 75 patients with stage I to II PTCL, there was no difference in outcomes among the 15 patients treated with combined modality therapy compared with 38 who received chemotherapy alone [<a href="#rid34">34</a>]. Median OS was 6.5 years and median event-free survival (EFS) was 2.1 years. When analyzing only the 40 patients who responded to induction chemotherapy, there was still no difference in OS or EFS between treatment modalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with stage I PTCL, NOS, the rates of OS and failure-free survival (FFS) were superior for 25 patients who received initial RT followed by chemotherapy, compared with 16 who received chemotherapy only in a retrospective study from the International Peripheral T-Cell Lymphoma (IPTCL) Project [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Addition of RT to chemotherapy was associated with improved OS and PFS in 35 patients with stage I to II PTCL, NOS in a single-institution study [<a href="#rid36">36</a>]. For patients treated with RT after chemotherapy, three-year OS and PFS rates were 50 and 33 percent, respectively, compared with 23 and 15 percent, respectively, for chemotherapy alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with chemotherapy alone, there was no difference in OS, PFS, or local control in patients who received RT after chemotherapy in a single-institution study of 39 patients with stage I to II PTCL [<a href="#rid37">37</a>].</p><p></p><p>Monitoring for relapse after completion of therapy is described below. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H59291752"><span class="h2">Advanced stage or adverse prognosis</span><span class="headingEndMark"> — </span>Postinduction management of patients with advanced-stage PTCL or an adverse prognostic score is guided by the end-of-induction response and eligibility for autologous HCT. (See <a class="local">'End-of-induction PET'</a> above.)</p><p class="headingAnchor" id="H2533521893"><span class="h3">Transplant-eligible patients</span><span class="headingEndMark"> — </span>Eligibility criteria for autologous HCT vary, but many institutions limit autologous HCT to patients ≤65 years or ≤70 years without major medical comorbidities. (See <a class="local">'Fitness/transplant eligibility'</a> above.)</p><p class="headingAnchor" id="H2401163789"><span class="h4">CR on end-of-induction PET</span><span class="headingEndMark"> — </span>For patients with CR on the end-of-induction PET, we suggest either observation or autologous HCT, rather than allogeneic HCT  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>). Autologous HCT is associated with acceptable toxicity, and there is limited evidence of more favorable outcomes compared with observation alone; by contrast, allogeneic HCT is associated with substantial toxicity that outweighs its potential benefits in this setting. </p><p>Selection of postinduction management should be individualized, using shared decision-making that weighs the risks and benefits of transplantation. This conversation should include recognition that autologous HCT may cause toxicity without providing a clear benefit for the individual patient, that it is not always possible to obtain a CR after relapse, and that relapsed PTCL has a dismal prognosis. </p><p class="bulletIndent1">Our approach is consistent with that of transplantation experts from the American Society of Blood and Marrow Transplantation [<a href="#rid38">38</a>], the United States National Comprehensive Cancer Network (NCCN) [<a href="#rid39">39</a>], and the European Society for Blood and Marrow Transplantation [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT versus observation</strong> – No randomized trials have directly compared autologous HCT with observation in this setting, and results from prospective and retrospective studies are mixed. Although there are trends toward more favorable outcomes with transplantation in patients with CR, these findings are subject to biases associated with nonrandomized studies of transplantation. As examples, transplant-eligible patients are usually fitter or younger compared with others, while transplantation is more frequently offered to those with more aggressive disease. In general, one-quarter to one-half of patients in prospective studies who planned to undergo autologous HCT did not do so, usually because of early disease progression or relapse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Meta-analyses</strong> – Comparison of autologous HCT versus observation yielded mixed results in meta-analyses:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A meta-analysis from 2014 reported a trend toward superior survival for patients who underwent autologous HCT in first complete response (CR1) for T cell lymphomas [<a href="#rid41">41</a>]. The study analyzed 1021 patients from 21 prospective studies, but most studies included patients who were transplanted in settings other than CR1 (eg, less than CR after induction, transplantation after relapse) or with other types of T cell lymphomas. Four of the studies compared outcomes after autologous HCT for PTCL in CR1 (128 patients) versus observation alone (468 patients); in these studies, there was no significant difference in survival with autologous HCT in CR1 (hazard ratio [HR] 0.81 [95% CI 0.31-2.13]). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Another meta-analysis reported widely divergent outcomes when comparing prospective studies versus retrospective studies of autologous HCT in CR1 [<a href="#rid42">42</a>]. Compared with 599 patients in 16 retrospective studies, 179 patients in 3 prospective studies had inferior outcomes with transplantation (overall survival [OS] 54 versus 68 percent; progression-free survival [PFS] 33 versus 55 percent), whereas transplantation-related mortality was 2 percent in prospective studies versus 6 percent in retrospective studies. The difference in outcomes may be due to better control of confounding factors in prospective studies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other studies</strong> - Results were also mixed from retrospective studies:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Swedish registry</strong> – Autologous HCT in CR1 was associated with superior outcomes in 128 patients with PTCL and enteropathy-associated T cell lymphoma (EATL) [<a href="#rid28">28</a>]. According to intention-to-treat analysis, and with median follow-up &gt;8 years, patients ≤70 years who underwent autologous HCT had superior OS (48 versus 26 percent; HR 0.58 [95% CI 0.40-0.84]) and PFS (41 versus 20 percent; HR 0.56 [95% CI 0.39-0.81]) compared with no transplantation. However, when analyzing only patients who were transplanted after achieving CR, there was no survival advantage for transplantation, according to univariate and multivariate analysis [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>COMPLETE</strong> – The Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) registry reported that compared with 83 patients who were not transplanted, 36 patients who underwent autologous transplantation in CR1 had superior OS (HR 0.37 [95% CI 0.15-0.89]) [<a href="#rid44">44</a>]. There were too few patients of any histologic subtype (35 patients had angioimmunoblastic T cell lymphoma [AITL]; 55 had PTCL, not otherwise specified [NOS]; 30 had anaplastic lymphoma kinase [ALK]-negative ALCL) to achieve statistical significance; however, for patients with AITL, two-year OS was 93 percent with autologous HCT versus 53 percent without transplantation, and the corresponding two-year PFS rates were 69 versus 41 percent, respectively.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>LYSA</strong> – This retrospective Lymphoma Study Association (LYSA) study reported no survival advantage with autologous HCT [<a href="#rid45">45</a>]. Among 269 patients (≤65 years) with PTCL (including 68 with ALK-positive ALCL) who achieved CR or PR after induction therapy, there was no difference in five-year OS for the 134 patients who were assigned to autologous HCT compared with 135 not assigned to transplantation; however, 16 percent of patients never proceeded to HCT, generally due to refractory disease.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dutch registry</strong> – This study reported superior outcomes with autologous HCT compared with observation, but more than one-third of patients had ALCL [<a href="#rid29">29</a>]. Among those transplanted in CR1, survival was superior with autologous HCT (84 percent five-year OS versus 47 percent).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Czech registry</strong> – This study reported no survival benefit for consolidation with autologous HCT [<a href="#rid18">18</a>]. Compared with no transplantation, five-year OS with autologous HCT did not differ significantly (49 percent with autologous HCT versus 60 percent without transplantation). However, among 79 patients selected for transplantation, three-quarters of patients never received the planned autologous HCT.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>United States multicenter</strong> <strong>study</strong> – A retrospective multicenter study reported improved survival for patients who underwent autologous HCT in CR1, but in multivariable analysis, this advantage was not seen when adjusted for initial treatment response [<a href="#rid46">46</a>]. More than one-half of patients had ALCL. Among 26 transplanted patients, three-year OS and PFS were 74 and 58 percent, respectively, compared with 53 and 30 percent among 211 patients who were observed without transplantation.</p><p></p><p class="bulletIndent1">An ongoing phase 3 trial by the LYSA group (TRANSCRIPT; NCT05444712) will randomly assign 204 patients with PTCL (excluding ALK-positive ALCL) to autologous HCT versus no consolidation therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous HCT versus allogeneic HCT</strong> - Allogeneic HCT can provide long-term disease control for patients with PTCL, but it is associated with greater toxicity and transplantation-related mortality than autologous HCT. Comparisons of transplantation techniques are confounded by the recognition that allogeneic HCT is usually performed in patients who did not reach CR, whereas autologous HCT is more commonly offered to patients who achieved CR [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1">Studies that compared transplantation techniques for patients in CR1 include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 3 clinical trial that was designed to compare autologous HCT versus allogeneic HCT in CR1 was closed prematurely in the face of high rates of transplant-related mortality with allogeneic HCT and interim analysis that indicated a significant survival difference was unlikely [<a href="#rid49">49</a>]. Three-year OS was similar between transplantation techniques (70 percent with autologous HCT versus 57 percent with allogeneic HCT), as were PFS and EFS. The causes of death differed between transplantation techniques; progressive disease accounted for most deaths in the autologous HCT group, whereas allogeneic HCT was associated with 31 percent nonrelapse mortality. There were no relapses among the patients who underwent allogeneic HCT, but 8 of 26 patients died of transplant-related toxicity. By comparison, for patients who underwent autologous HCT, there was no transplant-related mortality, but there were 13 relapses among 36 patients (36 percent). Approximately one-third of patients in both arms did not proceed to transplantation due to lack of response.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The phase 2 FIL study reported outcomes after autologous or allogeneic HCT in CR1 for patients with PTCL, but it was not powered to evaluate the differences between the two transplantation techniques [<a href="#rid50">50</a>]. Patients ≤60 years received allogeneic HCT or autologous HCT according to donor availability; 23 received allogeneic HCT, and 14 underwent autologous HCT. With median follow-up of 40 months, four-year OS, PFS, and disease-free survival rates were 49, 44, and 65 percent, respectively.</p><p></p><p>Other studies using autologous HCT or allogeneic HCT in CR1 for patients with PTCL are presented below. (See <a class="local">'Transplantation'</a> below.)</p><p class="headingAnchor" id="H317379601"><span class="h4">Less than CR</span><span class="headingEndMark"> — </span>For patients with less than CR on end-of-induction PET, management is guided by the nature of the residual disease  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial response (PR)</strong> <strong>with limited residual disease</strong> – For patients with limited residual disease (eg, a single residual site of PET activity) after induction therapy, we treat with radiation therapy (RT) plus autologous HCT.  </p><p></p><p class="bulletIndent1">We consider that the risk of relapse in this setting outweighs the AEs of autologous HCT. While we favor RT attempt to convert the PR to a CR before proceeding to autologous HCT, it is acceptable to proceed directly to autologous HCT and administer RT later.</p><p></p><p class="bulletIndent1">Comparisons of autologous HCT with observation or allogeneic HCT in patients with CR after induction therapy for PTCL are presented above. (See <a class="local">'CR on end-of-induction PET'</a> above.)</p><p></p><p class="bulletIndent1">Additional studies of autologous HCT and allogeneic HCT for PTCL are discussed below. (See <a class="local">'Transplantation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PR with more extensive residual disease, stable disease, or progressive disease</strong> – We treat patients with a PR that is not amenable to RT, stable disease, or progressive disease as relapsed/refractory (r/r) PTCL. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1964609195"><span class="h3">Not transplant eligible</span><span class="headingEndMark"> — </span>Postinduction management of patients who are not eligible for transplantation due to age (eg, &gt;65 years) or comorbid medical conditions is guided by the response to induction therapy and the location of disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CR</strong> <strong>or PR</strong> – For patients with CR or PR after induction chemotherapy, we offer RT to consolidate the response and then monitor the patients for disease relapse. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less than CR/PR</strong> – For patients with a response that is less than CR or PR, we offer RT to symptomatic sites of disease or manage as r/r PTCL. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H121740044"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>After completing therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and nature of follow-up visits depend on the comfort of both the patient and clinician.</p><p>Our approach to patient surveillance is to schedule patient visits every three to six months during the first two years, every six months in years 3 to 5, and then annually or as clinically indicated.</p><p>Monitoring includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – History and physical examination, complete blood count, chemistries, and lactate dehydrogenase (LDH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Surveillance positron emission tomography (PET) or CT no more than every six months for the first two years, then annually as clinically indicated.</p><p></p><p class="bulletIndent1">Care should be taken to limit PET and/or CT, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p></p><p>Relapse can be suggested by changes on imaging studies but must be confirmed by biopsy. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p class="headingAnchor" id="H4240184444"><span class="h1">TREATMENT MODALITIES</span></p><p class="headingAnchor" id="H3432920263"><span class="h2">Chemotherapy</span></p><p class="headingAnchor" id="H3008544486"><span class="h3">Standard induction regimens</span><span class="headingEndMark"> — </span>Selection of induction therapy for PTCL is described above. (See <a class="local">'Overview of management'</a> above.)</p><p>Standard induction regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BV+CHP</strong> (<a class="drug drug_general" data-topicid="16806" href="/d/drug information/16806.html" rel="external">brentuximab vedotin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>). (See <a class="local">'CD30 positive'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CHOEP</strong> (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, plus <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>). (See <a class="local">'Fit, younger patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CHOP</strong> (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>)  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>). (See <a class="local">'Older or less-fit patients'</a> above.)</p><p></p><p class="headingAnchor" id="H2154867044"><span class="h3">Other induction regimens</span><span class="headingEndMark"> — </span>Addition of agents to a CHOP backbone, intensification of therapy, and alternative agents have not been associated with superior outcomes for patients with PTCL and are generally more toxic than CHOP or CHOEP [<a href="#rid27">27</a>]. Most studies of these regimens included small numbers of patients. Only VIP-reinforced-ABVD (<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> alternating with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>) or addition of <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> or <a class="drug drug_general" data-topicid="9536" href="/d/drug information/9536.html" rel="external">romidepsin</a> to CHOP (described below) have been directly compared with CHOEP or CHOP in randomized trials.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VIP-reinforced-ABVD</strong> – A randomized trial of 88 evaluable patients with PTCL (including 10 with anaplastic lymphoma kinase [ALK]-positive anaplastic large cell lymphoma [ALCL]) reported that VIP-reinforced-ABVD was more toxic than CHOP but did not achieve superior outcomes [<a href="#rid51">51</a>]. VIP-reinforced-ABVD achieved 45 percent two-year event-free survival (EFS) compared with 41 percent two-year EFS with CHOP after median follow-up of nine years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alemtuzumab</strong><strong> plus CHOP</strong> – The phase 3 ACT-2 trial, which<strong> </strong>randomly assigned 116 patients with PTCL (excluding ALK-positive ALCL) to <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> plus CHOP (A-CHOP) versus CHOP, reported no differences in overall survival (OS), progression-free survival (PFS), or EFS, but response rates were higher with A-CHOP (60 percent complete response [CR] versus 43 percent) [<a href="#rid52">52</a>]. Compared with CHOP, A-CHOP caused more cytopenias, grade ≥3 infections (40 versus 21 percent), and deaths due to infections (four versus one).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Romidepsin</strong><strong> plus CHOP</strong> – The phase 3 <a class="drug drug_general" data-topicid="9536" href="/d/drug information/9536.html" rel="external">romidepsin</a> plus CHOP<strong> </strong>(Ro-CHOP) trial randomly assigned 421 patients (18 to 80 years) with PTCL (excluding ALK-positive ALCL) to Ro-CHOP versus CHOP [<a href="#rid53">53</a>]. There was no difference in two-year OS (64 versus 63 percent, respectively) or two-year PFS (43 versus 36 percent) for the entire population and no significant differences based on prespecified subgroup analysis. A retrospective subgroup analysis reported that for angioimmunoblastic T cell lymphoma (AITL) and other T follicular helper (TFH) cell PTCL, Ro-CHOP was associated with more prolonged PFS (median PFS 20 versus 11 months; hazard ratio [HR] 0.69 [95% CI 0.48-1.00]). Grade ≥3 thrombocytopenia (50 versus 10 percent), neutropenia (49 versus 33 percent), and anemia (47 versus 17 percent) were more common with Ro-CHOP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenalidomide</strong><strong> plus CHOP</strong> – Treatment of 71 patients with AITL reported 42 percent two-year PFS and 41 percent CR with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> plus CHOP; this was not appreciably better than treatment with CHOP in other studies [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-adjusted (DA)-EPOCH</strong> – Treatment with DA-EPOCH (<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>) reported 73 percent two-year OS and 53 percent two-year PFS in 41 patients (median age 64 years [range 32 to 79 years]; 17 patients had AITL and 21 had PTCL, not otherwise specified [NOS]) [<a href="#rid55">55</a>]. For the entire population, overall response rate (ORR) was 78 percent (including 61 percent CR), while for patients ≤60 years, ORR was 94 percent (including 71 percent CR). The most common grade ≥3 adverse events were neutropenia (75 percent), anemia (41 percent), thrombocytopenia (22 percent), and febrile neutropenia (9 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MegaCHOEP</strong> – The German High-Grade Non-Hodgkin Lymphoma Study Group reported 45 percent three-year OS and 26 percent three-year EFS with MegaCHOEP in 33 patients with PTCL (including 13 with ALK-negative ALCL) [<a href="#rid56">56</a>]. ORR was 56 percent (including 49 percent CR). Only two-thirds of patients received all planned therapy because of excessive toxicity in six patients, including two treatment-related deaths, and progressive or stable disease in four patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HyperCVAD</strong> – A retrospective single-institution study reported that, compared with CHOP, there was no improvement in three-year OS but more early treatment-related deaths with HyperCVAD (hyperfractionated <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>) [<a href="#rid57">57</a>]. The Australasian Leukaemia and Lymphoma Group reported that outcomes with modified HyperCVAD in 26 patients with PTCL were similar to outcomes with CHOP-like chemotherapy but were associated with significant toxicity [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GEM-P</strong> – The randomized, phase 2 CHEMO-T study compared GEM-P (<a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>) with CHOP in patients with PTCL (≥18 years; patients with ALK-positive ALCL were excluded) [<a href="#rid59">59</a>]. The trial was closed by the data monitoring board after enrollment of 87 patients, when the 46 percent CR rate with GEM-P appeared unlikely to be superior to CHOP (62 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azacitidine</strong><strong> plus </strong><strong>romidepsin</strong> – Treatment with <a class="drug drug_general" data-topicid="8797" href="/d/drug information/8797.html" rel="external">azacitidine</a> plus <a class="drug drug_general" data-topicid="9536" href="/d/drug information/9536.html" rel="external">romidepsin</a> in 10 treatment-naïve patients with PTCL was associated with 70 percent ORR (including 50 percent CR) in a multicenter phase 2 study [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H1331254227"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>The role of radiation therapy (RT) in managing PTCL is not well-defined, but we generally offer RT in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplant-eligible patients</strong> – Use of RT varies according to response, stage, and prognostic score:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Advanced-stage or adverse prognostic score</strong> – We offer RT in association with autologous transplantation to patients with PR after induction therapy, as discussed above. (See <a class="local">'Less than CR'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage I with favorable prognostic score</strong> – We offer adjuvant RT to consolidate a CR or PR. (See <a class="local">'Stage I with favorable prognostic score'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Not transplant eligible</strong> – We offer adjuvant RT to consolidate a CR or PR in patients with stage I PTCL who are not eligible for transplantation due to age or fitness. (See <a class="local">'Not transplant eligible'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom relief</strong> – RT can provide symptom relief as a component of management for relapsed or refractory PTCL or for palliation. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p>For patients who receive adjuvant RT, positron emission tomography (PET) is generally performed within 12 weeks after completing treatment [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1353838921"><span class="h2">Transplantation</span><span class="headingEndMark"> — </span>The role of hematopoietic cell transplantation (HCT) as consolidation therapy in first complete response (CR1) is discussed above. (See <a class="local">'Transplant-eligible patients'</a> above.)</p><p class="headingAnchor" id="H3489577844"><span class="h3">Autologous HCT</span><span class="headingEndMark"> — </span>Autologous hematopoietic cell transplantation (HCT) uses myeloablative conditioning therapy, followed by infusion of an autologous graft.</p><p>Comparisons of autologous HCT with observation or allogeneic HCT are presented above. (See <a class="local">'Transplant-eligible patients'</a> above.)</p><p>Other informative studies of autologous HCT for PTCL include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NLG-T-01</strong> – This prospective study by the Nordic Lymphoma Group (NLG) reported outcomes for 115 patients who underwent autologous HCT among 166 enrolled patients; 18 percent of patients had ALK-negative systemic anaplastic large cell lymphoma (sALCL) [<a href="#rid61">61</a>]. Five-year OS was 51 percent, five-year PFS was 44 percent, treatment-related mortality was 4 percent, and progression or relapse within two years occurred in 18 percent. Five-year outcomes according to disease subtype included AITL (52 percent OS, 49 percent PFS); PTCL, NOS (47 percent OS, 38 percent PFS); and enteropathy-associated T cell lymphoma (EATL; 48 percent OS, 38 percent PFS), but differences among subtypes were not statistically significant. A subsequent publication that added 28 new patients reported 44 percent five-year OS and 39 percent five-year PFS [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>German study</strong> – In a prospective study of 83 patients (including 32 with PTCL, NOS; 27 with AITL, 13 with ALK-negative sALCL), three-year OS and PFS were 48 and 36 percent, respectively [<a href="#rid63">63</a>]. Two-thirds of enrolled patients were able to proceed to autologous HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GEL-TAMO</strong> – This Spanish Grupo Español de Linfomas y Trasplantes de Médula Ósear (GEL-TAMO) reported that for 37 patients with PTCL (excluding ALK-positive ALCL), transplantation in CR1 was associated with 63 percent five-year PFS [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CIBMTR</strong> – Analysis of 39 patients with PTCL undergoing autologous HCT in CR1 in the Center for International Bone Marrow Transplant Registry (CIBMTR) database reported that the one-year OS and one-year PFS were 80 and 75 percent, respectively, while the three-year OS and PFS were 70 and 58 percent, respectively [<a href="#rid47">47</a>]. One-year and three-year nonrelapse mortality were 4 and 6 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Other studies that also reported outcomes with autologous HCT for PTCL included transplantation in settings other than CR1 or various T cell lymphomas [<a href="#rid16">16,17,65-75</a>].</p><p></p><p class="headingAnchor" id="H4211286878"><span class="h3">Allogeneic HCT</span><span class="headingEndMark"> — </span>There is no demonstrated role for allogeneic hematopoietic cell transplantation (HCT) in CR1 for patients with PTCL. Comparisons of allogeneic HCT with autologous HCT for PTCL are presented above. (See <a class="local">'CR on end-of-induction PET'</a> above.)</p><p></p><p>Other informative studies of allogeneic HCT in PTCL include:</p><p class="bulletIndent1"><span class="glyph">●</span>A registry study of 1942 patients who underwent allogeneic HCT for PTCL reported that rates of OS, PFS, relapse/progression, and nonrelapse mortality rate were similar for 237 patients who received haploidentical grafts with posttransplant <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> immunosuppression, compared with 1705 patients who received matched related or matched unrelated grafts [<a href="#rid76">76</a>]. Three-year OS and three-year PFS were approximately 60 and 50 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) registry reported that four-year OS was 63 percent, two-year relapse rate was 19 percent, and four-year transplant-related mortality was 24 percent for 138 patients who underwent allogeneic HCT in CR1 or first partial response [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single-center study reported outcomes for 29 patients with PTCL who proceeded to allogeneic HCT in CR1 (among 49 enrolled patients) [<a href="#rid78">78</a>]. For allogeneic HCT in CR1, one-year OS was 76 percent and two-year OS was 73 percent, compared with rates of 59 and 55 percent for the entire study population (including those who were transplanted). One-year toxicity-related mortality after allogeneic HCT was 8 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution retrospective study, 44 patients who underwent allogeneic HCT in CR1 had 54 percent five-year OS and 54 percent five-year PFS; 24 received reduced-intensity conditioning, and 20 received myeloablative conditioning [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">OUTCOMES BY PTCL SUBTYPE</span><span class="headingEndMark"> — </span>Because of their rarity, most studies of outcomes for patients with PTCL have included a variety of subtypes; only a few studies have focused on a specific subtype.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTCL, not otherwise specified (NOS)</strong> – Management of PTCL, NOS is described above. (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent1">PTCL, NOS has a dismal prognosis with low sensitivity to anthracycline-based chemotherapy [<a href="#rid80">80</a>]. The following studies reported outcomes for patients with PTCL, NOS who were mainly treated with CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study of PTCL, NOS by the IIL (Intergruppo Italiano Linfomi) registry reported that treatment with CHOP-like therapy was associated with 43 percent five-year overall survival (OS) and 53 percent complete response (CR) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study by the IPTCL (International Peripheral T-Cell Lymphoma Project) reported 32 percent five-year OS and 43 percent progression-free survival (PFS) for 340 patients with PTCL, NOS [<a href="#rid35">35</a>]. In this report, there was no difference in survival for patients treated with anthracycline-based combination chemotherapy compared with those receiving combination chemotherapy without an anthracycline.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective observational study by ITCP (International T-cell Project) reported 32 percent five-year OS and 23 percent five-year PFS [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among 70 patients with PTCL, NOS in a series of prospective German studies, three-year OS was 54 percent, and three-year event-free survival (EFS) was 41 percent [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of 64 patients with PTCL, NOS in a Korean study reported that after median follow-up of 30 months, three-year OS and PFS were 53 and 44 percent, respectively [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angioimmunoblastic T cell lymphoma</strong> <strong>(AITL) </strong>– AITL is the second most common subtype of PTCL.</p><p></p><p class="bulletIndent1">Analysis of several studies did not find a significant difference between CHOP and more intensive treatments, such as ACVBP (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10303" href="/d/drug information/10303.html" rel="external">vindesine</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) [<a href="#rid54">54</a>]. Other studies of AITL include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction regimens</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective study of 157 patients by Lymphoma Study Association (LYSA) in which patients received mainly CHOP and ACVBP reported 51 percent two-year OS, 38 percent two-year EFS, and 46 percent CR [<a href="#rid82">82</a>]. There was no difference in outcomes between CHOP and ACVBP.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective Japanese study of 207 patients, treated mainly with CHOP or THP-COP (pirarubicin, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a>), reported 54 percent three-year OS, 38 percent three-year PFS, and 66 percent CR [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A phase 2 study by LYSA of 25 patients treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (R)-CHOP reported 62 percent two-year OS, 42 percent two-year PFS, and 44 percent CR [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective study of 78 patients treated with lenalidomide-CHOP reported 59 percent two-year OS, 42 percent two-year PFS, and 41 percent CR [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A prospective, uncontrolled trial of 39 patients with AITL investigated a staged treatment approach in which patients were initially treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid85">85</a>]. Those who did not attain a CR with prednisone or who had life-threatening disease at diagnosis were treated with an anthracycline-based combination chemotherapy regimen. Compared with those who received prednisone therapy, patients treated with combination chemotherapy had superior CR rates (64 versus 29 percent, respectively) and a longer median survival (19 versus 11 months, respectively).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Analysis of 28 patients with AITL enrolled in prospective trials of CHOP or CHOP-like chemotherapy reported that the three-year OS and EFS were 68 and 50 percent, respectively [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autologous HCT</strong> – Retrospective studies have reported high rates of survival with autologous hematopoietic cell transplantation (HCT), especially for transplantation in first complete response (CR1) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective study of autologous HCT in 146 patients with AITL yielded 67 percent two-year OS and 59 percent four-year OS [<a href="#rid75">75</a>]. Compared with those who did not achieve CR, patients who had achieved a CR prior to autologous HCT had superior two-year PFS (70 versus 42 percent) and four-year PFS (56 versus 30 percent). Patients with refractory disease at the time of autologous HCT had the worst outcome (23 percent two-year PFS).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>An observational study by ITCP of 282 patients (treated mainly with CHOP) reported 50 percent three-year OS, 38 percent three-year PFS, and 51 percent CR [<a href="#rid10">10</a>]. Patients who underwent autologous transplantation in CR1 had better outcomes (five-year OS 89 percent and 79 percent five-year PFS) compared with transplant-eligible patients ≤65 years who did not undergo transplantation (52 percent five-year OS and 31 percent five-year PFS). The study also reported no significant difference in five-year OS for patients receiving chemotherapy regimens with <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> versus no etoposide (50 versus 43 percent, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Allogeneic HCT</strong> – A retrospective analysis of 45 patients with AITL who underwent myeloablative (25 patients) or reduced intensity conditioning allogeneic hematopoietic cell transplantation (HCT) reported one- and three-year OS rates of 66 and 64 percent, respectively, with 53 percent of patients being alive without disease progression at three years [<a href="#rid86">86</a>]. OS and PFS were significantly better for those patients with chemotherapy-sensitive disease at the time of HCT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enteropathy-associated T cell intestinal lymphoma (EATL)</strong> – This rare condition occurs most commonly in patients with gluten-sensitive enteropathy (ie, celiac disease).</p><p></p><p class="bulletIndent1">EATL is closely, but not exclusively, associated with celiac disease [<a href="#rid87">87</a>]. Many patients are malnourished at diagnosis, and they should be maintained on a gluten-free diet. Nutritional supplementation and vigorous control of infection are important because patients may experience intra-abdominal perforation, fistula formation, and infections (especially in those who required surgical resection) [<a href="#rid88">88,89</a>]. (See  <a class="medical medical_review" href="/d/html/4704.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1">Informative studies include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction therapy</strong> – Five-year OS with anthracycline-based chemotherapy alone is approximately 10 to 20 percent [<a href="#rid90">90-92</a>]. With HCT, case reports have suggested that some patients may achieve longer survival rates.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autologous HCT</strong> – Patients who achieve CR may benefit from autologous hematopoietic cell transplantation (HCT).</p><p></p><p class="bulletIndent2">As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A retrospective study of 26 patients with EATL treated with an intensive chemotherapy regimen (<a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>) followed by autologous HCT reported 60 percent five-year OS and 52 percent five-year PFS [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Another retrospective study of 44 patients with EATL treated with induction chemotherapy followed by autologous HCT reported four-year OS (59 percent), PFS (54 percent), and relapse rate (39 percent) at four years, respectively [<a href="#rid94">94</a>]. When compared with those with more advanced disease, patients in first CR or partial remission at the time of HCT had a trend towards improved survival at four years (66 versus 36 percent).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other studies have also reported outcomes of autologous HCT for EATL [<a href="#rid95">95-99</a>].</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Peripheral T cell lymphomas (PTCL) are uncommon, heterogeneous, and generally aggressive. This topic discusses management of: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PTCL, not otherwise specified (NOS)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Angioimmunoblastic T cell lymphoma (AITL)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enteropathy-associated T cell lymphoma (EATL)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – Includes classification of PTCL subtype, fitness, and prognosis. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Management is guided by tumor expression of CD30, fitness, and age. We use response-guided therapy for early recognition of inadequate responses and to enable prompt implementation of care for primary refractory disease. (See <a class="local">'Overview of management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – Stratified by tumor expression of CD30  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>) (see <a class="local">'Induction therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CD30 positive</strong> – For PTCL in which ≥1 percent of tumor cells express CD30, we suggest BV+CHP (<a class="drug drug_general" data-topicid="16806" href="/d/drug information/16806.html" rel="external">brentuximab vedotin</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>), rather than other regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'CD30 positive'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CD30 negative</strong> – Treatment of CD30-negative PTCL is guided by age and fitness:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Fit, younger patients</strong> – For fit, younger patients (eg, ≤65 years), we suggest CHOEP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>) rather than CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)  (<a class="graphic graphic_table graphicRef81762" href="/d/graphic/81762.html" rel="external">table 4</a>) or more intensive regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Fit, younger patients'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Older or less fit</strong> – For older or less-fit patients, we suggest CHOP, in order to avoid the increased toxicity with other regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Older or less-fit patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interim restaging</strong> - Restage with positron emission tomography (PET) after three initial induction cycles (PET3)  (<a class="graphic graphic_algorithm graphicRef142751" href="/d/graphic/142751.html" rel="external">algorithm 1</a>). (See <a class="local">'PET3 response'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete response (CR) or partial response (PR)</strong> – Finish original induction therapy (usually six cycles total). (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable or progressive disease</strong> – Manage for relapsed/refractory (r/r) PTCL. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-of-induction response</strong> – Repeat PET after completing induction therapy (see <a class="local">'End-of-induction PET'</a> above):</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postinduction management </strong>– Stratified by stage, prognosis, and fitness  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>). (See <a class="local">'Postinduction management'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I with favorable prognosis </strong>(See <a class="local">'Stage I with favorable prognostic score'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CR or PR</strong> - We suggest adjuvant radiation therapy (RT) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progressive disease</strong> - Treat for r/r PTCL (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced disease (stage II-IV or adverse prognosis) </strong>– Post-induction management is stratified as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transplant eligible </strong>– For fit, younger patients (eg, ≤65 years) with stage II to IV disease or adverse prognosis, management is guided by end-of-induction PET  (<a class="graphic graphic_algorithm graphicRef142873" href="/d/graphic/142873.html" rel="external">algorithm 2</a>) (see <a class="local">'Transplant-eligible patients'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CR</strong> – We suggest either observation or autologous hematopoietic cell transplantation (HCT), rather than allogeneic HCT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Limited residual disease</strong> – For limited residual disease (eg, a single persistent site), we suggest RT, followed by autologous HCT, rather than either intervention alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Extensive residual disease or progressive disease</strong> – Treat for r/r PTCL. (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Not</strong> <strong>transplant eligible</strong> (See <a class="local">'Not transplant eligible'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CR or limited residual disease</strong> - We suggest adjuvant RT (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>More extensive residual disease</strong> - Treat for r/r PTCL (See  <a class="medical medical_review" href="/d/html/4742.html" rel="external">"Treatment of relapsed or refractory peripheral T cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment modalities</strong> – Regimens and outcomes are discussed above. (See <a class="local">'Treatment modalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTCL subtypes</strong> – Outcomes for specific PTCL subtypes are presented. (See <a class="local">'Outcomes by PTCL subtype'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123:2915.</a></li><li><a class="nounderline abstract_t">Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 2019; 133:1664.</a></li><li><a class="nounderline abstract_t">Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014; 123:3007.</a></li><li><a class="nounderline abstract_t">Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 2019; 134:2159.</a></li><li><a class="nounderline abstract_t">Herek TA, Bouska A, Lone W, et al. DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood 2022; 140:1278.</a></li><li><a class="nounderline abstract_t">International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987.</a></li><li><a class="nounderline abstract_t">Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474.</a></li><li><a class="nounderline abstract_t">Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood 2021; 138:213.</a></li><li><a class="nounderline abstract_t">Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129:366.</a></li><li><a class="nounderline abstract_t">Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.</a></li><li><a class="nounderline abstract_t">Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15:2296.</a></li><li><a class="nounderline abstract_t">Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18:3025.</a></li><li><a class="nounderline abstract_t">Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350:1287.</a></li><li><a class="nounderline abstract_t">Niitsu N, Okamoto M, Nakamine H, et al. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 2008; 26:152.</a></li><li><a class="nounderline abstract_t">Yang DH, Kim WS, Kim SJ, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009; 15:118.</a></li><li><a class="nounderline abstract_t">Janikova A, Chloupkova R, Campr V, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol 2019; 98:1961.</a></li><li><a class="nounderline abstract_t">Corradini P, Marchetti M, Barosi G, et al. SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Ann Oncol 2014; 25:2339.</a></li><li class="breakAll">http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Accessed on December 23, 2014).</li><li><a class="nounderline abstract_t">Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153:451.</a></li><li><a class="nounderline abstract_t">d'Amore F, Gaulard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5:v108.</a></li><li><a class="nounderline abstract_t">Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 2022; 33:288.</a></li><li><a class="nounderline abstract_t">Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014; 123:3095.</a></li><li><a class="nounderline abstract_t">Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019; 393:229.</a></li><li><a class="nounderline abstract_t">Carson KR, Horwitz SM, Pinter-Brown LC, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer 2017; 123:1174.</a></li><li><a class="nounderline abstract_t">Sibon D. Peripheral T-Cell Lymphomas: Therapeutic Approaches. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014; 124:1570.</a></li><li><a class="nounderline abstract_t">Brink M, Meeuwes FO, van der Poel MWM, et al. Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study. Blood 2022; 140:1009.</a></li><li><a class="nounderline abstract_t">Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116:3418.</a></li><li><a class="nounderline abstract_t">Kim YA, Byun JM, Park K, et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv 2017; 1:2138.</a></li><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li><li><a class="nounderline abstract_t">Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.</a></li><li><a class="nounderline abstract_t">Briski R, Feldman AL, Bailey NG, et al. Survival in patients with limited-stage peripheral T-cell lymphomas. Leuk Lymphoma 2015; 56:1665.</a></li><li><a class="nounderline abstract_t">Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117:3402.</a></li><li><a class="nounderline abstract_t">Zhang XM, Li YX, Wang WH, et al. Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified. Int J Radiat Oncol Biol Phys 2013; 85:1051.</a></li><li><a class="nounderline abstract_t">Lee HK, Wilder RB, Jones D, et al. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 2002; 43:1769.</a></li><li><a class="nounderline abstract_t">Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2017; 23:1826.</a></li><li><a class="nounderline abstract_t">Horwitz SM, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw 2016; 14:1067.</a></li><li><a class="nounderline abstract_t">Snowden JA, Sánchez-Ortega I, Corbacioglu S, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022; 57:1217.</a></li><li><a class="nounderline abstract_t">Yin J, Wei J, Xu JH, et al. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis. Acta Haematol 2014; 131:114.</a></li><li><a class="nounderline abstract_t">El-Asmar J, Reljic T, Ayala E, et al. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biol Blood Marrow Transplant 2016; 22:802.</a></li><li><a class="nounderline abstract_t">Cederleuf H, Hjort Jakobsen L, Ellin F, et al. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leuk Lymphoma 2017; 58:2815.</a></li><li><a class="nounderline abstract_t">Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019; 125:1507.</a></li><li><a class="nounderline abstract_t">Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 2018; 29:715.</a></li><li><a class="nounderline abstract_t">Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014; 25:2211.</a></li><li><a class="nounderline abstract_t">Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31:3100.</a></li><li><a class="nounderline abstract_t">Du J, Yu D, Han X, et al. Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4:e219807.</a></li><li><a class="nounderline abstract_t">Schmitz N, Truemper L, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 2021; 137:2646.</a></li><li><a class="nounderline abstract_t">Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014; 28:1885.</a></li><li><a class="nounderline abstract_t">Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010; 151:159.</a></li><li><a class="nounderline abstract_t">Wulf GG, Altmann B, Ziepert M, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia 2021; 35:143.</a></li><li><a class="nounderline abstract_t">Bachy E, Camus V, Thieblemont C, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol 2022; 40:242.</a></li><li><a class="nounderline abstract_t">Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv 2021; 5:539.</a></li><li><a class="nounderline abstract_t">Maeda Y, Nishimori H, Yoshida I, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica 2017; 102:2097.</a></li><li><a class="nounderline abstract_t">Nickelsen M, Ziepert M, Zeynalova S, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009; 20:1977.</a></li><li><a class="nounderline abstract_t">Escalón MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005; 103:2091.</a></li><li><a class="nounderline abstract_t">Hapgood G, Stone JM, Zannino D, et al. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leuk Lymphoma 2019; 60:904.</a></li><li><a class="nounderline abstract_t">Gleeson M, Peckitt C, To YM, et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol 2018; 5:e190.</a></li><li><a class="nounderline abstract_t">Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021; 137:2161.</a></li><li><a class="nounderline abstract_t">d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30:3093.</a></li><li><a class="nounderline abstract_t">Wilhelm M, Smetak M, Reimer P, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J 2016; 6:e452.</a></li><li><a class="nounderline abstract_t">Reimer P, Rüdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27:106.</a></li><li><a class="nounderline abstract_t">García-Sancho AM, Bellei M, López-Parra M, et al. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. Haematologica 2022; 107:2675.</a></li><li><a class="nounderline abstract_t">Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20:1533.</a></li><li><a class="nounderline abstract_t">Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19:958.</a></li><li><a class="nounderline abstract_t">Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40:443.</a></li><li><a class="nounderline abstract_t">Rodríguez J, Caballero MD, Gutiérrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14:1768.</a></li><li><a class="nounderline abstract_t">Numata A, Miyamoto T, Ohno Y, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010; 45:311.</a></li><li><a class="nounderline abstract_t">Hosing C, Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 2011; 22:1471.</a></li><li><a class="nounderline abstract_t">Rodríguez J, Conde E, Gutiérrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79:32.</a></li><li><a class="nounderline abstract_t">Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88:1272.</a></li><li><a class="nounderline abstract_t">Rodríguez J, Conde E, Gutiérrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007; 78:290.</a></li><li><a class="nounderline abstract_t">Rodríguez J, Conde E, Gutiérrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18:652.</a></li><li><a class="nounderline abstract_t">Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:218.</a></li><li><a class="nounderline abstract_t">Hamadani M, Ngoya M, Sureda A, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv 2022; 6:920.</a></li><li><a class="nounderline abstract_t">Mamez AC, Dupont A, Blaise D, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). J Hematol Oncol 2020; 13:56.</a></li><li><a class="nounderline abstract_t">Loirat M, Chevallier P, Leux C, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015; 26:386.</a></li><li><a class="nounderline abstract_t">Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19:602.</a></li><li><a class="nounderline abstract_t">Pileri SA, Tabanelli V, Fiori S, et al. Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Federico M, Bellei M, Marcheselli L, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol 2018; 181:760.</a></li><li><a class="nounderline abstract_t">Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111:4463.</a></li><li><a class="nounderline abstract_t">Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 2012; 119:2837.</a></li><li><a class="nounderline abstract_t">Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica 2012; 97:1594.</a></li><li><a class="nounderline abstract_t">Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992; 117:364.</a></li><li><a class="nounderline abstract_t">Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27:3951.</a></li><li><a class="nounderline abstract_t">Al Somali Z, Hamadani M, Kharfan-Dabaja M, et al. Enteropathy-Associated T cell Lymphoma. Curr Hematol Malig Rep 2021; 16:140.</a></li><li><a class="nounderline abstract_t">Lennard A. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma. Br J Haematol 2007; 137:170; author reply 171.</a></li><li><a class="nounderline abstract_t">Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma - response to Lennard. Br J Haematol. 2007; 137:171.</a></li><li><a class="nounderline abstract_t">Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003; 21:2740.</a></li><li><a class="nounderline abstract_t">Egan LJ, Walsh SV, Stevens FM, et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995; 21:123.</a></li><li><a class="nounderline abstract_t">Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000; 18:795.</a></li><li><a class="nounderline abstract_t">Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010; 115:3664.</a></li><li><a class="nounderline abstract_t">Jantunen E, Boumendil A, Finel H, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood 2013; 121:2529.</a></li><li><a class="nounderline abstract_t">Okuda M, Nomura J, Tateno H, et al. CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation. Intern Med 2002; 41:734.</a></li><li><a class="nounderline abstract_t">Jantunen E, Juvonen E, Wiklund T, et al. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 2003; 44:2163.</a></li><li><a class="nounderline abstract_t">Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2007; 136:111.</a></li><li><a class="nounderline abstract_t">Halfdanarson TR, Rubio-Tapia A, Ristow KM, et al. Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol 2010; 8:1042.</a></li><li><a class="nounderline abstract_t">Nijeboer P, de Baaij LR, Visser O, et al. Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. Am J Hematol 2015; 90:493.</a></li></ol></div><div id="topicVersionRevision">Topic 4749 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24632715" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782609" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497534" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562134" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35639959" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141877" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A predictive model for aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645001" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292324" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842660" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626005" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196143" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944137" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044639" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18395866" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135950" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31065733" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723488" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723488" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21480860" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26314772" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34921960" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24652992" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30522922" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27911989" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35565460" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Peripheral T-Cell Lymphomas: Therapeutic Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006130" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544601" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of etoposide and ASCT on survival among patients aged&lt;65 years with stage II to IV PTCL: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660290" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296861" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242397" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25248884" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Survival in patients with limited-stage peripheral T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270441" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021436" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12685830" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797780" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27587620" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35589997" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24158006" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26713431" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28317459" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30694529" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253087" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193992" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897963" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34042995" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512419" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24662801" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20738307" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32382083" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34843406" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33496747" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28971899" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570965" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816054" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30547695" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703335" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33171487" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851556" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27471868" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029417" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35320921" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871285" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303032" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17589529" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630683" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597416" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21551006" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Stem-cell transplantation in T-cell non-Hodgkin's lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598836" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607756" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378891" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229774" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182664" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861680" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32429979" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the SociétéFrancophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25392158" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370119" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34572763" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29672827" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18292286" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22308294" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371178" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1380221" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620487" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34009525" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Enteropathy-Associated T cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17391498" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma - response to Lennard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860953" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8583077" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673521" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20197551" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361910" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12322803" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14959866" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116129" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851210" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25716069" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
